• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于预测接受膀胱保留治疗的肌层浸润性膀胱癌患者癌症特异性生存率的集成学习模型。

An ensemble learning model for predicting cancer-specific survival of muscle-invasive bladder cancer patients undergoing bladder preservation therapy.

作者信息

Wei Liwei, Wang Fubo, Yang Guanglin, Liao Naikai, Cui Zelin, Chen Hao, Zhao Qiyue, Qin Min, Cheng Ji-Wen

机构信息

Department of Urology, The First Affiliated Hospital, Guangxi Medical University, Nanning, China.

Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.

出版信息

Transl Cancer Res. 2024 Aug 31;13(8):4085-4095. doi: 10.21037/tcr-24-561. Epub 2024 Aug 27.

DOI:10.21037/tcr-24-561
PMID:39262460
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11385252/
Abstract

BACKGROUND

More muscle-invasive bladder cancer (MIBC) patients are now eligible for bladder-preserving therapy (BPT), underscoring the need for precision medicine. This study aimed to identify prognostic predictors and construct a predictive model among MIBC patients who undergo BPT.

METHODS

Data relating to MIBC patients were obtained from the Surveillance, Epidemiology and End Results (SEER) database from 2004 to 2016. Eleven features were included to establish multiple models. The predictive effectiveness was assessed using receiver operating characteristic (ROC) curves, calibration plots, decision curve analysis (DCA) and clinical impact curve (CIC). SHapley Additive exPlanations (SHAP) were used to explain the impact of features on the predicted targets.

RESULTS

The ROC showed that Catboost and Random Forest (RF) obtained better predictive discrimination in both 3- and 5-year models [test set area under curves (AUC) =0.80 and 0.83, respectively]. Furthermore, Catboost showed better performance in calibration plots, DCA and CIC. SHAP analysis indicated that age, M stage, tumor size, chemotherapy, T stage and gender were the most important features in the model for predicting the 3-year cancer-specific survival (CSS). In contrast, M stage, age, tumor size and gender as well as the N and T stages were the most important features for predicting the 5-year CSS.

CONCLUSIONS

The Catboost model exhibits the highest predictive performance and clinical utility, potentially aiding clinicians in making optimal individualized decisions for MIBC patients with BPT.

摘要

背景

现在更多的肌层浸润性膀胱癌(MIBC)患者符合保膀胱治疗(BPT)的条件,这凸显了精准医学的必要性。本研究旨在确定MIBC患者接受BPT后的预后预测因素并构建预测模型。

方法

从2004年至2016年的监测、流行病学和最终结果(SEER)数据库中获取与MIBC患者相关的数据。纳入11个特征以建立多个模型。使用受试者工作特征(ROC)曲线、校准图、决策曲线分析(DCA)和临床影响曲线(CIC)评估预测有效性。使用SHapley加性解释(SHAP)来解释特征对预测目标的影响。

结果

ROC显示,Catboost和随机森林(RF)在3年和5年模型中均获得了更好的预测区分度[测试集曲线下面积(AUC)分别为0.80和0.83]。此外,Catboost在校准图、DCA和CIC方面表现更好。SHAP分析表明,年龄、M分期、肿瘤大小、化疗、T分期和性别是预测3年癌症特异性生存(CSS)模型中最重要的特征。相比之下,M分期、年龄、肿瘤大小和性别以及N和T分期是预测5年CSS的最重要特征。

结论

Catboost模型表现出最高的预测性能和临床实用性,可能有助于临床医生为接受BPT的MIBC患者做出最佳的个体化决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/11385252/dbf4d57aec72/tcr-13-08-4085-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/11385252/0505e681336a/tcr-13-08-4085-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/11385252/85103bd47cda/tcr-13-08-4085-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/11385252/cd39b74c343d/tcr-13-08-4085-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/11385252/90bad2b0c4d4/tcr-13-08-4085-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/11385252/dbf4d57aec72/tcr-13-08-4085-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/11385252/0505e681336a/tcr-13-08-4085-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/11385252/85103bd47cda/tcr-13-08-4085-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/11385252/cd39b74c343d/tcr-13-08-4085-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/11385252/90bad2b0c4d4/tcr-13-08-4085-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/11385252/dbf4d57aec72/tcr-13-08-4085-f5.jpg

相似文献

1
An ensemble learning model for predicting cancer-specific survival of muscle-invasive bladder cancer patients undergoing bladder preservation therapy.一种用于预测接受膀胱保留治疗的肌层浸润性膀胱癌患者癌症特异性生存率的集成学习模型。
Transl Cancer Res. 2024 Aug 31;13(8):4085-4095. doi: 10.21037/tcr-24-561. Epub 2024 Aug 27.
2
Development and validation of a novel nomogram model for predicting the survival of patients with T2-4a, N0-x, M0 bladder cancer: a retrospective cohort study.一种用于预测T2-4a、N0-x、M0期膀胱癌患者生存率的新型列线图模型的开发与验证:一项回顾性队列研究
Am J Clin Exp Urol. 2023 Dec 15;11(6):500-515. eCollection 2023.
3
Prognostic nomogram for estimating survival in patients with resected muscle-invasive bladder cancer receiving chemotherapy.用于评估接受化疗的根治性肌肉浸润性膀胱癌患者生存情况的预后列线图。
Front Surg. 2023 Feb 24;10:1121184. doi: 10.3389/fsurg.2023.1121184. eCollection 2023.
4
Nomograms for predicting the overall and cancer-specific survival in patients with non-urothelial carcinoma of the bladder: A population-based study.预测非尿路上皮膀胱癌患者总生存和癌症特异性生存的列线图:一项基于人群的研究。
Biomol Biomed. 2024 May 2;24(3):633-646. doi: 10.17305/bb.2023.9881.
5
Population-based outcome of muscle-invasive bladder cancer following radical cystectomy: who can benefit from adjuvant chemotherapy?根治性膀胱切除术后肌层浸润性膀胱癌的人群预后:谁能从辅助化疗中获益?
Transl Androl Urol. 2021 Jan;10(1):356-373. doi: 10.21037/tau-20-960.
6
Development and validation of competing risk nomograms for predicting cancer‑specific mortality in non-metastatic patients with non‑muscle invasive urothelial bladder cancer.开发和验证列线图模型预测非转移性非肌肉浸润性膀胱癌患者的癌症特异性死亡率的竞争风险。
Sci Rep. 2024 Jul 31;14(1):17641. doi: 10.1038/s41598-024-68474-9.
7
Predictive nomograms for risk and prognostic factors in metastatic bladder cancer: a population-based study.转移性膀胱癌风险及预后因素的预测列线图:一项基于人群的研究。
Transl Cancer Res. 2023 Dec 31;12(12):3284-3302. doi: 10.21037/tcr-23-1229. Epub 2023 Dec 21.
8
Identification of prognostic factors for predicting survival of patients with malignant adrenal tumors: A population-based study.预测恶性肾上腺肿瘤患者生存的预后因素识别:一项基于人群的研究。
Front Oncol. 2022 Oct 17;12:930473. doi: 10.3389/fonc.2022.930473. eCollection 2022.
9
Development and validation of prognostic nomograms for early-onset colon cancer in different tumor locations: a population-based study.不同肿瘤部位早发性结肠癌预后列线图的建立与验证:基于人群的研究。
BMC Gastroenterol. 2023 Oct 21;23(1):362. doi: 10.1186/s12876-023-02991-1.
10
Development and validation of a nomogram model for cancer-specific survival of patients with poorly differentiated thyroid carcinoma: A SEER database analysis.基于 SEER 数据库分析建立低分化甲状腺癌患者癌症特异性生存的列线图模型并验证
Front Endocrinol (Lausanne). 2022 Sep 13;13:882279. doi: 10.3389/fendo.2022.882279. eCollection 2022.

本文引用的文献

1
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
2
The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer.选择性肌层浸润性膀胱癌保留膀胱的三联疗法的疗效。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211062323. doi: 10.1177/15330338211062323.
3
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials.
辅助化疗治疗肌层浸润性膀胱癌:随机对照试验个体参与者数据的系统评价和荟萃分析。
Eur Urol. 2022 Jan;81(1):50-61. doi: 10.1016/j.eururo.2021.09.028. Epub 2021 Nov 19.
4
Data mining in clinical big data: the frequently used databases, steps, and methodological models.临床大数据中的数据挖掘:常用数据库、步骤和方法学模型。
Mil Med Res. 2021 Aug 11;8(1):44. doi: 10.1186/s40779-021-00338-z.
5
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.帕博利珠单抗单药治疗卡介苗(BCG)无应答的高风险非肌肉浸润性膀胱癌(KEYNOTE-057):一项开放标签、单臂、多中心、2 期研究。
Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26.
6
Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.当代及新兴的肌层浸润性膀胱癌保膀胱三联疗法。
Hematol Oncol Clin North Am. 2021 Jun;35(3):567-584. doi: 10.1016/j.hoc.2021.02.006. Epub 2021 Apr 15.
7
Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer.保留膀胱的三模态疗法治疗肌层浸润性膀胱癌患者的长期结果。
Acta Oncol. 2021 Jun;60(6):794-802. doi: 10.1080/0284186X.2021.1915498. Epub 2021 Apr 27.
8
Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.新辅助化疗指导下的保膀胱治疗肌层浸润性膀胱癌:一项Ⅱ期研究的初步结果。
Cancer Res Treat. 2021 Oct;53(4):1156-1165. doi: 10.4143/crt.2020.1356. Epub 2021 Feb 10.
9
Logistic Regression in Medical Research.医学研究中的逻辑回归
Anesth Analg. 2021 Feb 1;132(2):365-366. doi: 10.1213/ANE.0000000000005247.
10
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.欧洲泌尿外科学会肌层浸润性和转移性膀胱癌指南:2020 年指南摘要。
Eur Urol. 2021 Jan;79(1):82-104. doi: 10.1016/j.eururo.2020.03.055. Epub 2020 Apr 29.